Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors

Inclusion Criteria:

• Histologically confirmed advanced solid tumor

  • Refractory to standard therapy or no standard therapy exists
• Evaluable disease

• No known untreated CNS metastases

  • Patients who have undergone local treatment for brain metastases and whose brain metastases are stable by repeat imaging study performed ≤ 4 weeks after treatment are allowed
• No primary CNS tumors
• Performance status - Karnofsky 60-100%
• WBC ≥ 3,500/mm^3
• Neutrophil count ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• Bilirubin ≤ 1.5 mg/dL
• AST and ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN for liver metastases)
• Creatinine ≤ 1.5 mg/dL
• No cardiac arrhythmias within the past 6 months
• No congestive heart failure within the past 6 months
• No myocardial infarction within the past 6 months
• No arterial or venous thrombosis within the past year
• No peripheral neuropathy > grade 1
• No other medical condition that would preclude study participation
• No serious or uncontrolled infection
• HIV negative

• Not pregnant or nursing

  • No nursing during and for 2 months after study participation
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 2 months after study participation
• At least 2 weeks since prior immunotherapy
• At least 2 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin)
• No prior flavopiridol
• At least 2 weeks since prior radiotherapy
• Recovered from all prior therapy

• No concurrent therapy for thrombosis

  • Prophylaxis for central lines or deep vein thrombosis allowed
• No other concurrent investigational medications

• No concurrent vitamins, antioxidants, or herbal preparations and supplements

  • Concurrent single-tablet multivitamin allowed